TD2 and Deep 6 AI collaborate to find cancer patients for appropriate clinical trials in minutes


Oncology development organisation Translational Drug Development (TD2) has entered into a formal agreement with US-based company Deep 6 AI to collaborate in the fields of oncology and fibrosis.

Under the deal, the two parties will collaborate to rapidly match eligible cancer patients with appropriate clinical trials.

The partnership will provide TD2 with access to Deep 6 AI’s artificial intelligence to identify potential clinical trial participants in minutes.

The Deep 6 AI system has the ability to assess all structured and unstructured clinical data, including physician notes, and pathology and genomic reports.

It helps quicken the process of matching patients with new drug trials that help find suitable participants in minutes instead of the months it takes to manually review patient records.

"Partnering with Deep 6 AI allows TD2 to provide patients with rapid access to the newest, most advanced medicines."

TD2 chief executive officer Stephen Gately said: “Partnering with Deep 6 AI allows TD2 to provide patients with rapid access to the newest, most advanced medicines.

“Our sponsor companies benefit from more timely study enrolment and patient identification that precisely matches study protocols, increasing the opportunity to demonstrate clinical activity for new medicines earlier in development.”

The new approach enables TD2 to continuously monitor the number of eligible patients with specific cancers who can participate in a clinical study.

The company will also be able to identify patient populations that are rare in an incidence or genomic context to define trial and regulatory opportunities, as well as develop dynamic protocols with inclusion / exclusion criteria based on real-time patient data.

Deep 6 AI CEO Wout Brusselaers said: “The partnership will advance our shared mission of getting cutting-edge treatments to patients more quickly.

“We’re thrilled to offer TD2 the ability to mine real-time patient data to guide trial feasibility and design, site selection and patient enrolment. Together we will significantly accelerate medical research.”